REDWOOD CITY, Calif.--(BUSINESS WIRE)--Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today the initiation of the RETIME 2.0 (Resynchronization using Electric Tomography to Improve Myocardial Efficiency 2.0) study. RETIME 2.0 is designed to assess the performance of Proteus Biomedical’s cardiac electric tomography (CET) and multi-sensor lead system for the measurement of cardiac performance in heart failure patients undergoing implantation of a cardiac resynchronization therapy (CRT) device.
